Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (231-240 of 302) with videos related to

Pageof 31
Sort By:
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
British Journal of Cancer|October 21, 2025
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort studyGarazi Ruiz de Azua, Idlir Licaj, Sandrine Pinto, et al.
The New England Journal of Medicine|December 14, 2011
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerJosé Baselga, Mario Campone, Martine Piccart, et al.
Advances in Therapy|October 26, 2013
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisDenise A Yardley, Shinzaburo Noguchi, Kathleen I Pritchard, et al.
Cancer|March 30, 2025
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network studyAlexandre Bertucci, Ondine Dufour, Romain Appay, et al.
Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.
Plos One|October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersPaul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
Pageof 31

Showing results (231-240 of 302) with videos related to

Sort By:
Pageof 31
Breast Cancer (Tokyo, Japan)|January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohortLaetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
British Journal of Cancer|October 21, 2025
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort studyGarazi Ruiz de Azua, Idlir Licaj, Sandrine Pinto, et al.
The New England Journal of Medicine|December 14, 2011
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerJosé Baselga, Mario Campone, Martine Piccart, et al.
Advances in Therapy|October 26, 2013
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisDenise A Yardley, Shinzaburo Noguchi, Kathleen I Pritchard, et al.
Cancer|March 30, 2025
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network studyAlexandre Bertucci, Ondine Dufour, Romain Appay, et al.
Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.
Plos One|October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersPaul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
Pageof 31